Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

NCT02981745 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Waldenstrom's Macroglobulinemia
Mantle Zone Lymphoma Refractory/Recurrent
Follicle Centre Lymphoma Diffuse
Diffuse Large B Cell Lymphoma

Interventions

DRUG: CT-1530

Sponsor

Centaurus Biopharma Co., Ltd.